Hong Kong-based private equity firm PAG is investing up to $200 million in Indian drugmaker RK Pharma, which has a focus on complex injectables.
- RK Pharma’s products include mitomycin injection vials, a cancer drug.
- The investment will help RK Pharma accelerate its growth plans, partnerships, and develop and launch further innovative medicines.
- PAG’s investment is a massive endorsement of RK Pharma’s strong research and development capabilities and unique positioning in the broader injectable CDMO space.
- This is PAG’s fifth India-focused private equity deal in recent years, with other investments including Nuvama, Acme Formulation, and Optimus Drugs.
- PAG has invested more than $1.5 billion in India in the last few years.
- PAG manages $50 billion in assets and has invested more than $70 billion, mostly in Asia.